Human Laboratory Study of Apremilast for Alcohol Use Disorder

Overview

Primary: The primary objective of this study is to compare the efficacy of two different maintenance doses of apremilast (tablets) in reducing alcohol craving among subjects with moderate to severe alcohol use disorder (AUD) after two weeks of daily dosing. Secondary: Secondary objectives include evaluation of two different maintenance doses of apremilast compared with matched placebo on other measures of self-reported alcohol consumption, alcohol craving, alcohol-related negative consequences, AUD symptoms, pain, sleep disturbances, depression, anxiety, quality of life, cigarette smoking, other nicotine use, cannabis use, retention in the study, and safety.

Interventions

• Drug Placebo
  Matched Placebo Capsule
• Drug Apremilast
  30 mg capsule

Primary outcome measures

• Alcohol Craving [Time frame: Week 4]

Secondary outcome measures (12)

• Participants with no heavy drinking days [Time frame: Weeks 2-5]
• Participants abstinent from alcohol [Time frame: Weeks 2-5]
• Days abstinent from alcohol per week. [Time frame: Weeks 2-5]
• Participants with at least a WHO 2-level decrease in alcohol consumption [Time frame: Weeks 2-5]
• Heavy drinking days per week [Time frame: Weeks 2-5]
• Participants abstinent from cigarette smoking [Time frame: Weeks 4-5]
• Number of drinks per week [Time frame: Weeks 2-5]
• Number of drinks per drinking day [Time frame: Weeks 2-5]
• Alcohol Use Disorder Symptoms [Time frame: Week 6]
• Number of days of cannabis use per week [Time frame: Weeks 4-6]
• Global Health Score [Time frame: Weeks 4,6]
• Alcohol Negative Consequences Score [Time frame: Weeks 4,6]

Eligibility criteria

Inclusion Criteria (not exhaustive list):

• Be at least 21 years of age.
• Have a current (past 12 months) DSM-5 diagnosis of AUD (4 or more symptoms) assessed using the MINI neuropsychiatric interview version 7.0.2 (at least moderate severity).
• Have a BAC by breathalyzer equal to 0.000 when s/he signed the informed consent document (either just prior to or immediately after signing consent).
• Be seeking treatment for problems with alcohol and express a goal of abstinence or a reduction in drinking.
• Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
• Agree (if the participant is female and of childbearing potential) to use at least one of the following methods of birth control, unless she is surgically sterile, partner is surgically sterile or she is postmenopausal:

• oral contraceptives,
• contraceptive sponge,
• patch,
• double barrier (diaphragm/spermicidal or condom/spermicidal),
• intrauterine contraceptive system,
• etonogestrel implant,
• medroxyprogesterone acetate contraceptive injection,
• complete abstinence from sexual intercourse, and/or
• hormonal vaginal contraceptive ring.
• Be willing to adhere to the investigational product dosing schedule.
• Complete all assessments required at screening and baseline.
• Have a place to live in the 2 weeks prior to randomization and not be at risk that s/he will lose his/her housing by Study Week 6.
• Not anticipate any significant problems with transportation arrangements or available time to travel to the study site by Study Week 6.
• Not have any plans to move within Study Week 6 to a location which would make continued participation in the study impractical.
• Provide contact information of someone, such as a family member, spouse, or significant other, who may be able to contact the participant in case of a missed clinic appointment.
• Be someone who in the opinion of the investigator would be expected to complete the study protocol.
• Agree to the schedule of visits, verbally acknowledge that s/he will be able to attend each scheduled visit, participate in phone visits and that s/he does not have any already scheduled events or a job that may substantially interfere with study participation.
• If taking a medication for depression, must have been taking a stable dose in the 2-months prior to randomization and plan to continue during the study. This includes drugs such as the following:

• SSRIs
• Dual uptake inhibitors
• SNRIs
• Tricyclic antidepressants
• MAOIs
• Bupropion
• Not currently taking apremilast and agree not to take non-study supplied apremilast for the duration of the study.
• Have normal renal function defined as creatinine clearance ≥ 60 mL per minute by the Cockcroft-Gault equation.

Exclusion criteria

Contact study site for exclusion criteria

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Triple blind

Primary purpose

Treatment

Study locations

United States · 3 centers

• University of California — Los Angeles
• University of Colorado — Aurora
• University of Virginia — Charlottesville

Identifiers

NCT: NCT07325266 · HLAB-004

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗